目的评估碘克沙醇对中国慢性肾病患者行经皮冠状动脉介入治疗(PCI)术后发生主要不良心脑血管事件(MACCE)和对比剂诱发急性肾损伤(CIAKI)的影响。方法自2013年10月30日至2015年10月9日在中国的30个中心入选3042例患者,对入选的患者住院...目的评估碘克沙醇对中国慢性肾病患者行经皮冠状动脉介入治疗(PCI)术后发生主要不良心脑血管事件(MACCE)和对比剂诱发急性肾损伤(CIAKI)的影响。方法自2013年10月30日至2015年10月9日在中国的30个中心入选3042例患者,对入选的患者住院期间观察3 d,出院后随访1个月。根据患者是否存在慢性肾病分为慢性肾病组(105例)和非慢性肾病组(2937例)。主要研究终点为住院期间即PCI术后72 h MACCE(包括靶病变再次血运重建、卒中、支架内血栓、心源性死亡及心肌梗死)和CIAKI的发生率。次要终点为PCI术后72 h^30 d的MACCE发生率。结果 (1)慢性肾病组患者年龄[(66.28±9.32)岁比(62.89±10.90)岁,P=0.003]、高血压病(83.81%比59.14%,P<0.001)、充血性心力衰竭(15.24%比1.94%,P<0.001)、血脂异常(73.33%比57.44%,P=0.001)、糖尿病(51.43%比23.90%,P<0.001)、消化性溃疡(6.67%比2.86%,P=0.036)及缺血性卒中(20.00%比9.02%,P<0.001)比例均高于非慢性肾病组,既往应用抗高血压药(83.81%比69.83%,P=0.002)、利尿药(11.43%比4.09%,P=0.002)、调脂药物(84.76%比74.60%,P=0.018)、降糖药物(43.81%比17.23%,P<0.001)、抗血小板聚集药物(94.29%比78.21%,P<0.001)和抗凝药物(39.05%比24.28%,P=0.001)比例均高于非慢性肾病组,差异均有统计学意义。(2)慢性肾病组和非慢性肾病组患者手术路径(桡动脉路径92.38%比96.97%,尺动脉路径5.71%比2.83%,股动脉路径0.95%比0.03%,肱动脉路径0.95%比0.17%;P=0.006)、术前水化容积[(905.94±486.04)ml比(521.20±344.76)ml,P<0.001]、术后水化容积[(859.00±433.97)ml比(712.42±419.74)ml,P=0.011]、水化总量[(1407.78±773.45)ml比(976.20±592.68)ml,P<0.001]、术后病变狭窄程度[(2.10±3.81)%比(1.04±4.15)%,P<0.001]、对比剂剂量[(114.48±52.44)ml比(141.35±57.86)ml,P<0.001]和机器注射对比剂流率[(3.38±1.02)ml/s比(4.67±1.29)ml/s,P<0.001]等围术期指标比较,差异均有统计学意义。(3)慢性肾病组PCI术后应用β阻滞药(11.43%比19.31%,P=0.043)、调脂药物(17.14%比28.77%,P=0.009)、他汀类药物(16.19%比27.99%,P=0.008)及抗血小板聚集药物(28.57%比39.94%,P=0.019)比例均低于非慢性肾病组患者,差异均有统计学意义。(4)两组患者住院期间及PCI术后72 h^30 d MACCE发生率比较,差异均无统计学意义(均P>0.05)。(5)两组患者住院期间CIAKI发生率比较,差异无统计学意义(P>0.05)。结论碘克沙醇对行PCI的中国慢性肾病患者与非慢性肾病患者MACCE和CIAKI发生率无显著影响。展开更多
目的探讨不同年龄段冠状动脉慢性完全闭塞(chronic total occlusions,CTO)病变患者的临床、影像学及经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的特点。方法回顾性分析北部战区总医院心内科2009年1月至2014年12月...目的探讨不同年龄段冠状动脉慢性完全闭塞(chronic total occlusions,CTO)病变患者的临床、影像学及经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的特点。方法回顾性分析北部战区总医院心内科2009年1月至2014年12月连续收治行PCI的CTO患者1951例。按年龄分为青年组(≤44岁)117例、中年组(45~59岁)773例和老年组(≥60岁)1061例。患者临床特征、冠状动脉造影结果、PCI相关资料及住院结果均来源于我院心内科冠心病PCI数据库。结果青年组、中年组和老年组患者在男性比例(100.0%比91.2%比66.4%,P<0.001)、体重指数[(26.9±3.6)kg/m2比(26.3±5.0)kg/m2比(25.2±3.7)kg/m2,P<0.001]、吸烟者比例(73.5%比68.6%比47.2%,P<0.001)、饮酒者比例(45.3%比43.9%比27.0%,P<0.001)、肌酐清除率[(129.6±34.5)ml/min比(110.2±32.7)ml/min比(83.7±28.6)ml/min,P<0.001]、血三酰甘油[(2.75±2.88)mmol/L比(2.52±2.27)mmol/L比(1.96±1.32)mmol/L,P<0.001]、低密度脂蛋白胆固醇[(2.61±1.19)mmol/L比(2.36±0.95)mmol/L比(2.32±0.89)mmol/L,P=0.011]等方面比较,差异均有统计学意义,且青年组均为最高值;而不稳定型心绞痛者比例(61.5%比78.8%比75.1%,P<0.001)、高血压病者比例(52.1%比54.5%比66.1%,P<0.001)及卒中病史者比例(0.0比6.3%比10.0%,P<0.001)比较,差异均有统计学意义,但青年组均为最低值;病变血管支数[(2.19±0.76)支比(2.19±0.77)支比(2.30±0.73)支,P=0.005]及CTO闭塞时间[(11.7±2.8)个月比(26.3±8.6)个月比(26.7±8.4)个月,P=0.002]比较,差异均有统计学意义,且青年组均为最低值;靶血管成功率(86.8%比89.0%比84.1%,P=0.009)、完全血运重建率(40.2%比36.6%比31.5%,P=0.026)和平均支架直径[(2.90±0.28)mm比(2.84±0.28)mm比(2.82±0.28)mm,P=0.018]比较,差异均有统计学意义。三组患者CTO血管分布、侧支循环Rentrop分级值、CTO病变长度、CTO病变直径和CTO病变特征(刀切状CTO、CTO存在桥侧支和CTO病变近端有分支)、对比剂剂量、CTO手术时间、平均支架数和平均支架长度方面比较,差异均无统计学差异(均P>0.05)。结论青年CTO患者具有典型的传统冠心病危险因素,且可能由于病史时间较短,使其具有较高的靶血管成功率和完全血运重建率。冠心病危险因素的控制应贯彻于疾病预防的始终。展开更多
Background Coronary stents are widely used in percutaneous coronary intervention (PCI) procedures. We aimed to explore the incidence, predictors and characteristics of stent thrombosis (ST) after coronary stent i...Background Coronary stents are widely used in percutaneous coronary intervention (PCI) procedures. We aimed to explore the incidence, predictors and characteristics of stent thrombosis (ST) after coronary stent implantation in routine clinical practice. Methods From data of 18 063 consecutive patients who underwent successful stent implantation in Shenyang Northern Hospital from 2004 to 2010, we identified patients with definite ST (n=140) and control patients (n=280) matched on age, diagnosis, sex, current antiplatelet medication and stent type. The incidence, predictors and characteristics of ST after coronary stent implantation were investigated.Results The incidence of angiographically confirmed ST was 0.78% (140/18 063). The time distribution of ST was acute in 43 (30.7%), subacute in 50 (35.7%), and late in 47 (33.6%) patients. Binary Logistic regression analysis identi?ed the angiotensin-converting enzyme inhibitor (ACEI) (odds ratio (OR)=0.472, 95% CI: 0.276–0.807, P=0.006) and heparin (OR=0.477, 95% CI: 0.278–0.819, P=0.007) were associated with an reduced risk of cumulative ST. Stent length (OR=1.042, 95% CI: 1.026–1.058, P 〈0.001), serum creatinine total (OR=1.020, 95% CI: 1.004–1.035, P=0.04), cholesterol (OR=1.267, 95% CI: 1.021–1.573, P=0.032), glucose (OR=1.086, 95% CI: 1.002–1.176, P=0.044), and platelet aggregation (OR=1.113, 95% CI: 1.075–1.154, P 〈0.001) were associated with an increased risk of cumulative ST. Conclusion ST is associated with longer stent length and higher level of total cholesterol, glucose and platelet aggregation.展开更多
Background Currently intra-aortic balloon pump (IABP) has been widely used in patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI). However, few studies have been done...Background Currently intra-aortic balloon pump (IABP) has been widely used in patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI). However, few studies have been done with regard to the clinical outcome and safety of IABP in assisting PCI in aged patients with ACS. The purpose of the present study was to evaluate the safety of tABP in different age groups of patients with ACS.Methods Data on 292 ACS patients who received IABP-assisted PCI in Shenyang General Hospital of People's Liberation Army were retrospectively analyzed. More specifically, the successful rate, mortality and complications associated with the treatment were compared between the senior (〉60 years old) and the non-senior (〈60 years old) groups of patients. Results The attack rate of non-ST segment elevation ACS was significantly higher in the senior group than in the non-senior group (38.8% vs 21.1%, P 〈0.01). The incidence of the IABP-associated complications was not significantly different between both groups (P 〉0.05).Conclusion The clinical outcome and safety of IABP-assisted PCI in the elderly patients were comparable to that for the non-elderly patients.展开更多
Background Some larger scale, randomized studies have demonstrated the superiority of drug-eluting stents (DES) over bare metal stents (BMS) for the treatment of acute myocardial infarction (AMI). This study aim...Background Some larger scale, randomized studies have demonstrated the superiority of drug-eluting stents (DES) over bare metal stents (BMS) for the treatment of acute myocardial infarction (AMI). This study aimed to investigate the impact of DES, in comparison with BMS, on the 2-year clinical outcomes in patients with ST-elevation myocardial infarction (STEMI).Methods From January 2002 to December 2008, a total of 1301 consecutive STEMI patients treated with coronary stenting in Shenyang Northern Hospital were prospectively registered. Patients received BMS (n=868) or DES (n=435) implantation in the infarction related artery according to physician's discretion. A propensity score analysis was performed and two well matched subgroups were selected (BMS, n=288; DES, n=288) to evaluate the 2-year clinical outcomes. The primary outcome was the occurrence of major adverse cardiac events (MACE), which was defined as a composite of all-cause death, myocardial infarction (MI), or target vessel revascularization (TVR).Results Survival salvage analysis showed that 2-year cumulative hazards were not significantly different between the two groups with respect to TVR (2.8% vs. 3.1%, log-rank P=0.780), stent thrombosis (1.7% vs. 4.2%, log-rank P=0.079) and MACE (8% vs. 10.8%, log-rank P=0.236). Multivariate analysis showed that DES was an independent protective factor of MI (HR: 0.211, 95% CI: 0.049 to 0.908) and stent thrombosis (HR: 0.327, 95% CI: 0.107 to 0.994).Conclusion DES was associated with similar 2-year clinical outcomes to those of BMS for the treatment of STEMI in daily practice.展开更多
文摘目的评估碘克沙醇对中国慢性肾病患者行经皮冠状动脉介入治疗(PCI)术后发生主要不良心脑血管事件(MACCE)和对比剂诱发急性肾损伤(CIAKI)的影响。方法自2013年10月30日至2015年10月9日在中国的30个中心入选3042例患者,对入选的患者住院期间观察3 d,出院后随访1个月。根据患者是否存在慢性肾病分为慢性肾病组(105例)和非慢性肾病组(2937例)。主要研究终点为住院期间即PCI术后72 h MACCE(包括靶病变再次血运重建、卒中、支架内血栓、心源性死亡及心肌梗死)和CIAKI的发生率。次要终点为PCI术后72 h^30 d的MACCE发生率。结果 (1)慢性肾病组患者年龄[(66.28±9.32)岁比(62.89±10.90)岁,P=0.003]、高血压病(83.81%比59.14%,P<0.001)、充血性心力衰竭(15.24%比1.94%,P<0.001)、血脂异常(73.33%比57.44%,P=0.001)、糖尿病(51.43%比23.90%,P<0.001)、消化性溃疡(6.67%比2.86%,P=0.036)及缺血性卒中(20.00%比9.02%,P<0.001)比例均高于非慢性肾病组,既往应用抗高血压药(83.81%比69.83%,P=0.002)、利尿药(11.43%比4.09%,P=0.002)、调脂药物(84.76%比74.60%,P=0.018)、降糖药物(43.81%比17.23%,P<0.001)、抗血小板聚集药物(94.29%比78.21%,P<0.001)和抗凝药物(39.05%比24.28%,P=0.001)比例均高于非慢性肾病组,差异均有统计学意义。(2)慢性肾病组和非慢性肾病组患者手术路径(桡动脉路径92.38%比96.97%,尺动脉路径5.71%比2.83%,股动脉路径0.95%比0.03%,肱动脉路径0.95%比0.17%;P=0.006)、术前水化容积[(905.94±486.04)ml比(521.20±344.76)ml,P<0.001]、术后水化容积[(859.00±433.97)ml比(712.42±419.74)ml,P=0.011]、水化总量[(1407.78±773.45)ml比(976.20±592.68)ml,P<0.001]、术后病变狭窄程度[(2.10±3.81)%比(1.04±4.15)%,P<0.001]、对比剂剂量[(114.48±52.44)ml比(141.35±57.86)ml,P<0.001]和机器注射对比剂流率[(3.38±1.02)ml/s比(4.67±1.29)ml/s,P<0.001]等围术期指标比较,差异均有统计学意义。(3)慢性肾病组PCI术后应用β阻滞药(11.43%比19.31%,P=0.043)、调脂药物(17.14%比28.77%,P=0.009)、他汀类药物(16.19%比27.99%,P=0.008)及抗血小板聚集药物(28.57%比39.94%,P=0.019)比例均低于非慢性肾病组患者,差异均有统计学意义。(4)两组患者住院期间及PCI术后72 h^30 d MACCE发生率比较,差异均无统计学意义(均P>0.05)。(5)两组患者住院期间CIAKI发生率比较,差异无统计学意义(P>0.05)。结论碘克沙醇对行PCI的中国慢性肾病患者与非慢性肾病患者MACCE和CIAKI发生率无显著影响。
文摘目的探讨不同年龄段冠状动脉慢性完全闭塞(chronic total occlusions,CTO)病变患者的临床、影像学及经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)的特点。方法回顾性分析北部战区总医院心内科2009年1月至2014年12月连续收治行PCI的CTO患者1951例。按年龄分为青年组(≤44岁)117例、中年组(45~59岁)773例和老年组(≥60岁)1061例。患者临床特征、冠状动脉造影结果、PCI相关资料及住院结果均来源于我院心内科冠心病PCI数据库。结果青年组、中年组和老年组患者在男性比例(100.0%比91.2%比66.4%,P<0.001)、体重指数[(26.9±3.6)kg/m2比(26.3±5.0)kg/m2比(25.2±3.7)kg/m2,P<0.001]、吸烟者比例(73.5%比68.6%比47.2%,P<0.001)、饮酒者比例(45.3%比43.9%比27.0%,P<0.001)、肌酐清除率[(129.6±34.5)ml/min比(110.2±32.7)ml/min比(83.7±28.6)ml/min,P<0.001]、血三酰甘油[(2.75±2.88)mmol/L比(2.52±2.27)mmol/L比(1.96±1.32)mmol/L,P<0.001]、低密度脂蛋白胆固醇[(2.61±1.19)mmol/L比(2.36±0.95)mmol/L比(2.32±0.89)mmol/L,P=0.011]等方面比较,差异均有统计学意义,且青年组均为最高值;而不稳定型心绞痛者比例(61.5%比78.8%比75.1%,P<0.001)、高血压病者比例(52.1%比54.5%比66.1%,P<0.001)及卒中病史者比例(0.0比6.3%比10.0%,P<0.001)比较,差异均有统计学意义,但青年组均为最低值;病变血管支数[(2.19±0.76)支比(2.19±0.77)支比(2.30±0.73)支,P=0.005]及CTO闭塞时间[(11.7±2.8)个月比(26.3±8.6)个月比(26.7±8.4)个月,P=0.002]比较,差异均有统计学意义,且青年组均为最低值;靶血管成功率(86.8%比89.0%比84.1%,P=0.009)、完全血运重建率(40.2%比36.6%比31.5%,P=0.026)和平均支架直径[(2.90±0.28)mm比(2.84±0.28)mm比(2.82±0.28)mm,P=0.018]比较,差异均有统计学意义。三组患者CTO血管分布、侧支循环Rentrop分级值、CTO病变长度、CTO病变直径和CTO病变特征(刀切状CTO、CTO存在桥侧支和CTO病变近端有分支)、对比剂剂量、CTO手术时间、平均支架数和平均支架长度方面比较,差异均无统计学差异(均P>0.05)。结论青年CTO患者具有典型的传统冠心病危险因素,且可能由于病史时间较短,使其具有较高的靶血管成功率和完全血运重建率。冠心病危险因素的控制应贯彻于疾病预防的始终。
文摘Background Coronary stents are widely used in percutaneous coronary intervention (PCI) procedures. We aimed to explore the incidence, predictors and characteristics of stent thrombosis (ST) after coronary stent implantation in routine clinical practice. Methods From data of 18 063 consecutive patients who underwent successful stent implantation in Shenyang Northern Hospital from 2004 to 2010, we identified patients with definite ST (n=140) and control patients (n=280) matched on age, diagnosis, sex, current antiplatelet medication and stent type. The incidence, predictors and characteristics of ST after coronary stent implantation were investigated.Results The incidence of angiographically confirmed ST was 0.78% (140/18 063). The time distribution of ST was acute in 43 (30.7%), subacute in 50 (35.7%), and late in 47 (33.6%) patients. Binary Logistic regression analysis identi?ed the angiotensin-converting enzyme inhibitor (ACEI) (odds ratio (OR)=0.472, 95% CI: 0.276–0.807, P=0.006) and heparin (OR=0.477, 95% CI: 0.278–0.819, P=0.007) were associated with an reduced risk of cumulative ST. Stent length (OR=1.042, 95% CI: 1.026–1.058, P 〈0.001), serum creatinine total (OR=1.020, 95% CI: 1.004–1.035, P=0.04), cholesterol (OR=1.267, 95% CI: 1.021–1.573, P=0.032), glucose (OR=1.086, 95% CI: 1.002–1.176, P=0.044), and platelet aggregation (OR=1.113, 95% CI: 1.075–1.154, P 〈0.001) were associated with an increased risk of cumulative ST. Conclusion ST is associated with longer stent length and higher level of total cholesterol, glucose and platelet aggregation.
文摘Background Currently intra-aortic balloon pump (IABP) has been widely used in patients with acute coronary syndrome (ACS) who undergo percutaneous coronary intervention (PCI). However, few studies have been done with regard to the clinical outcome and safety of IABP in assisting PCI in aged patients with ACS. The purpose of the present study was to evaluate the safety of tABP in different age groups of patients with ACS.Methods Data on 292 ACS patients who received IABP-assisted PCI in Shenyang General Hospital of People's Liberation Army were retrospectively analyzed. More specifically, the successful rate, mortality and complications associated with the treatment were compared between the senior (〉60 years old) and the non-senior (〈60 years old) groups of patients. Results The attack rate of non-ST segment elevation ACS was significantly higher in the senior group than in the non-senior group (38.8% vs 21.1%, P 〈0.01). The incidence of the IABP-associated complications was not significantly different between both groups (P 〉0.05).Conclusion The clinical outcome and safety of IABP-assisted PCI in the elderly patients were comparable to that for the non-elderly patients.
基金This study was supported by grants from the National Natural Science Foundation of China (NSFC) (No. 30800465) and Science and Technical Foundation of Liaoning Province (No. 20092090).
文摘Background Some larger scale, randomized studies have demonstrated the superiority of drug-eluting stents (DES) over bare metal stents (BMS) for the treatment of acute myocardial infarction (AMI). This study aimed to investigate the impact of DES, in comparison with BMS, on the 2-year clinical outcomes in patients with ST-elevation myocardial infarction (STEMI).Methods From January 2002 to December 2008, a total of 1301 consecutive STEMI patients treated with coronary stenting in Shenyang Northern Hospital were prospectively registered. Patients received BMS (n=868) or DES (n=435) implantation in the infarction related artery according to physician's discretion. A propensity score analysis was performed and two well matched subgroups were selected (BMS, n=288; DES, n=288) to evaluate the 2-year clinical outcomes. The primary outcome was the occurrence of major adverse cardiac events (MACE), which was defined as a composite of all-cause death, myocardial infarction (MI), or target vessel revascularization (TVR).Results Survival salvage analysis showed that 2-year cumulative hazards were not significantly different between the two groups with respect to TVR (2.8% vs. 3.1%, log-rank P=0.780), stent thrombosis (1.7% vs. 4.2%, log-rank P=0.079) and MACE (8% vs. 10.8%, log-rank P=0.236). Multivariate analysis showed that DES was an independent protective factor of MI (HR: 0.211, 95% CI: 0.049 to 0.908) and stent thrombosis (HR: 0.327, 95% CI: 0.107 to 0.994).Conclusion DES was associated with similar 2-year clinical outcomes to those of BMS for the treatment of STEMI in daily practice.